New Brunswick, NJNCT07260916Now EnrollingIRB Ready

Basal Ganglia Intracerebral Hemorrhage Clinical Trial in New Brunswick, NJ

Access cutting-edge basal ganglia intracerebral hemorrhage treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Icahn School of Medicine at Mount Sinai

Quick Self-Assessment

See if you qualify for this New Brunswick location

Preparing your pre-screening questions…

Expert Care in New Brunswick

Access basal ganglia intracerebral hemorrhage specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related basal ganglia intracerebral hemorrhage treatment provided free

Apply for This New Brunswick Location

Check if you qualify for this basal ganglia intracerebral hemorrhage clinical trial in New Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Brunswick site if eligible
  4. 4Begin participation

About This Basal Ganglia Intracerebral Hemorrhage Study in New Brunswick

MINUTE is a prospective, multi-center, randomized, controlled, blinded assessor, adaptive enrichment design, clinical trial. Eligible patients with spontaneous BGH ≥20 mL will be randomized 1:1 to either minimally invasive endoscopic SCUBA evacuation plus standard medical management or standard medical management alone; the time of randomization will be used to classify participants in one of two cohorts: 1) those randomized \<8 hours from onset, and 2) those randomized 8-16 hours from onset. Randomization is targeted to occur within 120 min of arrival to the randomizing center's Emergency Department (ED), and initiation of surgery is targeted to occur within 120 min of randomization. Participants will be followed at 30, 90, 180, and 365 days to assess for adverse events (AEs) and utility-weighted modified Rankin Scale (UW-mRS).

Sponsor: Icahn School of Medicine at Mount Sinai

Who Can Participate

Inclusion Criteria

Age ≥ 18 and ≤ 80 years
Non-traumatic, spontaneous, supratentorial, non-thalamic, BGH of volume ≥ 20 mL, as determined by the treating physician using ABC/2 method
NIHSS ≥ 6 at presentation
Computed Tomography Angiography (CTA) or Magnetic Resonance Angiography (MRA) is performed and does not show an underlying vascular lesion
Pre-ICH mRS 0-2 Informed consent from patient or legally authorized representative (LAR) to participate in the trial, wherein patient/LAR's stated wishes are to pursue lifesaving therapies as opposed to early withdrawal of care (explicitly explained as \<7 days following ictus)
The treating physician anticipates that surgery can be initiated \<120 min from randomization
Randomization can occur ≤16 hours from LKW

Exclusion Criteria

Suspected secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct Infratentorial or thalamic hemorrhage
Midbrain extension/involvement
Coagulopathy defined as international normalized ratio (INR) \> 1.4
Elevated activated Partial Thromboplastin Time (aPTT) \> 40 s
Concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset
Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency
Platelet count \<100 x 103 cells/mm3, or known platelet dysfunction (reversal of coagulopathy is not allowed) GCS score \<7 at presentation
Evidence of active infection indicated by fever ≥100.7 °F and/or open draining wound at the time of enrollment
Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 365 days
Intraventricular extension of the hemorrhage is visually estimated to involve \> 50% of either of the lateral ventricles
Pregnancy (women of childbearing potential must have a negative pregnancy test to participate)
Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up schedule
Current participation in another interventional (drug or device) trial
Pre-existing Do Not Resuscitate (DNR)/Do Not Intubate (DNI) status
History of severe dementia

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Brunswick?

Yes, this clinical trial (NCT07260916) has an active research site in New Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Basal Ganglia Intracerebral Hemorrhage Treatment Options in New Brunswick, NJ

If you're searching for basal ganglia intracerebral hemorrhage treatment options in New Brunswick, NJ, this clinical trial (NCT07260916) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced basal ganglia intracerebral hemorrhage specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all basal ganglia intracerebral hemorrhage clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in New Brunswick, NJ

See all rheumatoid arthritis clinical trials recruiting in New Brunswick — not just this study.

Browse Rheumatoid Arthritis Trials in New Brunswick →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in New Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Brunswick, NJ